The effects of anti-lung cancer in nude mice by a fully human single-chain antibody against associated antigen Ts7TMR between A549 cells and Trichinella spiralis
Source abstract
Abstract
Lung cancer is a dangerous disease that is lacking in an ideal therapy. Here, we evaluated the anti-lung cancer effect in nude mice of a fully human single-chain antibody (scFv) against the associated antigen 7 transmembrane receptor (Ts7TMR), which is also called G protein-coupled receptor, between A549 cells and Trichinella spiralis (T. spiralis). Our data showed that anti-Ts7TMR scFv could inhibit lung cancer growth in a dose-dependent manner, with a tumour inhibition rate of 59.1%. HE staining did not reveal any obvious tissue damage. Mechanistically, immunohistochemical staining revealed that the scFv down-regulated the expression of PCNA and VEGF in tumour tissues. Overall, this study found that anti-Ts7TMR scFv could inhibit A549 lung cancer growth by suppressing cell proliferation and angiogenesis, which may provide a new strategy for treating lung cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun, China
First Hospital, Jilin University, Changchun, China
Funding
Science and Technology Development Program of Jilin Province · National Key Research and Development Program of China
References (44)
Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1111/joim.1344510.1111/joim.13445 ↗
3. 10.1038/s41591-018-0146-z10.1038/s41591-018-0146-z ↗
4. 10.1016/j.ejca.2016.09.01010.1016/j.ejca.2016.09.010 ↗
5. 10.1002/cpt.305710.1002/cpt.3057 ↗
6. 10.1007/s11356-021-17090-510.1007/s11356-021-17090-5 ↗
7. 10.1016/j.intimp.2023.10970810.1016/j.intimp.2023.109708 ↗
8. 10.1016/j.vetpar.2013.02.02110.1016/j.vetpar.2013.02.021 ↗
9. 10.2174/187152061766617112111584710.2174/1871520617666171121115847 ↗
10. 10.1051/parasite/202004510.1051/parasite/2020045 ↗
11. 10.1016/j.actatropica.2021.10617210.1016/j.actatropica.2021.106172 ↗
12. 10.1016/j.vetpar.2008.10.05210.1016/j.vetpar.2008.10.052 ↗
13. 10.1016/j.vetpar.2013.01.05210.1016/j.vetpar.2013.01.052 ↗
14. 10.1016/j.vetpar.2013.01.05010.1016/j.vetpar.2013.01.050 ↗
15. 10.1016/j.vetpar.2013.01.05110.1016/j.vetpar.2013.01.051 ↗
16. 10.1016/j.exppara.2010.12.00110.1016/j.exppara.2010.12.001 ↗
17. 10.1186/s13071-021-05008-610.1186/s13071-021-05008-6 ↗
18. Zhang TJ, Pang DX, Zhang N, et al. Preparation of monoclonal antibody against Trichinella spiralis selenoprotein T and its inhibitory effect on hepatoma H7402 cells in nude mice. Chin J Biologicals January. 2020;33:42–44. (in Chinese).
19. 10.1039/D0RA08534K10.1039/D0RA08534K ↗
20. 10.1016/j.intimp.2019.03.02010.1016/j.intimp.2019.03.020 ↗
21. 10.1016/j.tranon.2021.10122710.1016/j.tranon.2021.101227 ↗
22. 10.3390/ijms2216870610.3390/ijms22168706 ↗
23. Wang JP, Zhang GL, Zhang HY, et al. Screening of A549 cells-associated scFv antibody against Trichinella spiralis antigen protein 7TR. Chin J Biol. 2017;30:488–492. (in Chinese).
24. 10.1186/1756-9966-29-8510.1186/1756-9966-29-85 ↗
25. 10.3390/v1305086810.3390/v13050868 ↗
26. 10.1038/s41392-022-01270-x10.1038/s41392-022-01270-x ↗
27. 10.1186/s12943-023-01844-510.1186/s12943-023-01844-5 ↗
28. 10.3389/fmolb.2021.73821910.3389/fmolb.2021.738219 ↗
29. 10.1021/nn202410f10.1021/nn202410f ↗
30. 10.1002/jcb.2873210.1002/jcb.28732 ↗
31. 10.1038/s41598-019-41567-610.1038/s41598-019-41567-6 ↗
32. 10.1073/pnas.150708711210.1073/pnas.1507087112 ↗
33. 10.1016/j.yexcr.2020.11227810.1016/j.yexcr.2020.112278 ↗
34. 10.1038/nrc323610.1038/nrc3236 ↗
35. 10.1038/sj.onc.120710410.1038/sj.onc.1207104 ↗
36. 10.1002/ar.2384210.1002/ar.23842 ↗
37. 10.1080/10717544.2022.206345410.1080/10717544.2022.2063454 ↗
38. 10.1586/eci.09.3110.1586/eci.09.31 ↗
39. 10.1186/s13054-017-1678-110.1186/s13054-017-1678-1 ↗
40. 10.1007/s00432-019-02857-810.1007/s00432-019-02857-8 ↗
41. 10.1186/s12929-024-00998-810.1186/s12929-024-00998-8 ↗
42. 10.1146/annurev.immunol.25.022106.14160910.1146/annurev.immunol.25.022106.141609 ↗
43. 10.1200/jco.23.0001310.1200/jco.23.00013 ↗
44. 10.1016/j.lungcan.2018.03.02510.1016/j.lungcan.2018.03.025 ↗